Central nervous system recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
| Agomelatine (Valdoxan®) for depression (NETAG) | Recommendation | Recommended for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses | 13/07/2010 | |
| Aripiprazole long acting injection (Abilify Maintena®) for schizophrenia | Recommendation North of England Guidance | Recommended as per the North of England Guidance | 09/04/2015 | |
| Buprenorphine prolonged release injection for opioid dependence | Recommendation | Recommended as alternative option for the management of opioid dependence after oral methadone and/or oral buprenorphine | 07/09/2021 | |
| Doxylamine/Pyridoxine (Xonvea®) for nausea & vomiting in pregnancy | Recommendation | Not currently recommended pending further national guidance | 23/02/2021 | |
| e-Voke® electronic cigarette for smoking cessation | Recommendation | Not recommended | 05/04/2016 | |
| Lurasidone (Latuda®▼) for the treatment of schizophrenia in adults and adolescents aged 13 years and over | Recommendation | Recommended as an option only for the treatment of schizophrenia in adults and adolescents aged 13 years and older meeting the criteria in the recommendation | 07/09/2021 | |
| Lycra Garments for the management of cerebral palsy and other neurological or musculoskeletal conditions | Recommendation | Not recommended | 25/02/2020 | |
| Paliperidone long-acting monthly(Xepilon®) and three monthly (Trevicta®) injection for schizophrenia | Recommendation North of England Guidance | Recommended as per the North of England Guidance | 05/09/2017 | |
| Perampanel (Fycompa®) for Partial-onset (focal) epilepsy (NETAG) | Recommendation | Recommended only when other treatment options recommended by NICE have been tried or fully considered | 08/06/2021 | |
|
Updated 22/02/2022 |
Pitolisant (Wakix®) for the treatment of narcolepsy with or without cataplexy in adults | Recommendation Appeal Appraisal Pitolisant (Wakix®) Treatment Pathway | Recommended as per the regionally agreed guidance | 22/02/2022 |
| Qutenza® (capsaicin patch) for neuropathic pain (updated) | Recommendation Qutenza® Treatment Pathway | Recommended as a fourth line agent in line with treatment pathway | 06/06/2017 | |
| Sativex® for the treatment of non-MS pain | Recommendation | Not recommended | 25/02/2020 | |
|
Updated 31/01/2023 |
Sodium oxybate(Xyrem®) for Narcolepsy with Cataplexy in adult patients (updated) | NTAG Decision Summary - Sodium Oxybate for narcolepsy - updated Nov 2022 - final | Recommended | 15/11/2022 |
| Solriamfetol for obstructive sleep apnoea in adults | Recommendation | Not recommended for use ahead of NICE TA | 08/12/2020 | |
| Transcutaneous vagus nerve stimulation for treatment of cluster headache and migraine | Recommendation | Recommended for Cluster Headache only (updated) | 08/06/2021 | |
| Voke® Inhaler Nicotine Replacement Therapy for Smoking Cessation | Recommendation | Not recommended as a stop smoking aid on the NHS or for prescribing by GPs | 25/02/2020 | |
|
New 09/05/2023 |
North East North Cumbria (NENC) ICB Medicines Committee Position Statement on Prescribing in Persistent Pain | NENC ICB position-statement-non-palliative-care-use-of-opiates update April 23 | Approved | 18/04/2023 |